Nasdaq
$15.70▼ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $838.5MShares out 53.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.24After-hours26.09.25 05:054Ownership#●●●
Aktis Oncology, Inc.
Aktis Oncology, Inc. insider Akos Czibere filed a Form 4 on September 24, 2026, reporting a change in beneficial ownership of securities as of September 23, 2026. This filing reflects standard insider activity regarding the company's equity.…more
$15.70-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.23After-hours26.09.24 05:20144Ownership
Aktis Oncology, Inc.
Insider Czibere Akos of Aktis Oncology, Inc. has filed an SEC Form 144 to report a proposed sale of company securities. This is a standard filing disclosing the insider's plan to dispose of shares.…more
$15.70-0.13%vs prev closeView filingShare - 7.22Overnight26.07.22 09:504Ownership
Aktis Oncology, Inc.
Aktis Oncology, Inc.의 경영진인 Ken Herrmann이 2026년 7월 20일에 자사 주식 10,000주를 매입했습니다. 이는 회사 경영진의 주식 매입으로, 회사의 미래 성장 가능성에 대한 긍정적인 신호로 해석될 수 있습니다.…more
$15.70-0.13%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 21:04#●●●#●●●
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
Aktis Oncology has launched a second Phase 1b clinical trial for its drug candidate AKY-2519, targeting patients with non-small cell lung cancer. The company is also conducting a separate trial for prostate cancer, with preliminary results anticipated in 2027.…more
$15.70-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.13After-hours26.08.14 05:01
●●●●●●●● ●●●●● ●●●●●●
Aktis Oncology announced its second-quarter financial results alongside updates on its key clinical pipelines, AKY-1189 and AKY-2519. With a strong cash position, the company has secured operating funds through 2029 to support its ongoing research and development efforts.…more
$15.70-0.13%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report